NCT00697008已完成不适用
Symptomatic Assessment and Therapeutic Outcomes in Typical GERD Patients Following a New CP Guideline in the Clinical Practice
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Symptomatic outcome of GERD management following new guideline
研究概览
简要总结
To evaluate symptomatic outcome and HRQoL in GERD patients treated following a new CP Guideline.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 17 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age above 18
- •Subjects with typical GERD symptoms: predominant heartburn/regurgitation
- •Naive patients or off PPI treatment in the last 2 months
排除标准
- •Inability to read and understand PRO instructions
- •Patient not suitable to be treated following the AEG guidelines
- •Concomitant treatment with NSAID, antiplatelet drugs
- •Previous PPI failure
结局指标
主要结局
Symptomatic outcome of GERD management following new guideline
时间窗: End of study visit 4-8w
次要结局
- To evaluate the frequency and type of extraesophageal and dyspeptic symptoms and their impact on the clinical outcome(End of study 4-8w)
- To evaluate the impact of GERD symptoms in HRQoL(End of study 4-8w)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The analysis of QOL in the patients of GERD with chronic liver disease after the treatment of PPI or H2-BThe patients of GERD with chronic liver diseaseJPRN-UMIN000002941CHiba University hospital100
已完成
4 期
Esomeprazole in PPI Failures - IMPROVEGastroesophageal Reflux DiseaseNCT00272701AstraZeneca450
已完成
不适用
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese PopulationGastroesophageal Reflux DiseaseNCT00165022Chinese University of Hong Kong330
终止
不适用
Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux SurgeryNon-acid Reflux DiseaseNCT01241149United States Naval Medical Center, Portsmouth12
已完成
不适用
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)GERDNCT00567619AstraZeneca900